Monte Rosa Therapeutics, Inc. GLUE
We are a clinical-stage biotechnology company developing a portfolio of novel and proprietary molecular glue degraders, or MGDs. MGDs are small molecule drugs that employ the body's natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins, in effect editing the human proteome. MGDs function by inducing the engagement of an E3 ligase, such as cereblon, with defined structural features on surfaces of target proteins. These target proteins are also referred to as neosubstrates. The E3 ligase then tags the target protein for degradation by adding a molecular mark known as ubiquitin. We believe our MGDs provide significant advantages over existing therapeutic modalities, including other protein degradation approaches.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $123.7M | $75.6M | $0 | — | — | — | — |
| R&D | $141.5M | $121.6M | $111.3M | $85.1M | $57.2M | $24.0M | — |
| SG&A | $36.4M | $35.2M | $32.0M | $27.3M | $15.7M | $4.0M | — |
| Total operating expenses | $177.9M | $156.7M | $143.3M | $112.4M | $72.9M | $28.0M | — |
| Operating income | -$54.2M | -$81.1M | -$143.3M | -$112.4M | -$72.9M | -$28.0M | — |
| Pre-tax income | -$39.7M | -$70.1M | -$135.0M | -$108.5M | — | — | — |
| Income tax | $1.1M | $2.6M | $338.0K | $0 | — | — | — |
| Net income | -$38.6M | -$72.7M | -$135.4M | -$108.5M | -$74.0M | -$35.9M | — |
| EPS, diluted | — | — | — | — | -2.96 | -23.65 | — |
| Shares, diluted (wtd. avg.) | 83.1M | 73.9M | 51.4M | 47.2M | 25.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $129.9M | $224.3M | $132.7M | $60.2M | $351.4M | $42.9M | $9.2M |
| Total current assets | $393.2M | $377.4M | $236.2M | $275.9M | $348.7M | $43.6M | — |
| Property, plant and equipment | $26.0M | $29.5M | $33.8M | $27.1M | $12.3M | $4.6M | — |
| Total assets | $448.7M | $438.7M | $303.8M | $342.4M | $366.3M | $49.4M | — |
| Accounts payable | $3.5M | $17.2M | $11.2M | $7.9M | $6.6M | $7.1M | — |
| Total current liabilities | $64.2M | $156.9M | $46.6M | $25.6M | $16.6M | $29.3M | — |
| Total liabilities | $215.6M | $215.8M | $124.5M | $71.0M | $18.8M | $30.3M | — |
| Retained earnings | -$477.2M | -$438.6M | -$365.9M | -$230.5M | -$122.0M | -$48.1M | — |
| Total equity | $233.1M | $222.9M | $179.2M | $271.4M | $347.5M | -$48.7M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.8M | $42.0M | -$43.8M | -$92.5M | -$59.4M | -$23.1M | — |
| Depreciation and amortisation | $8.4M | $8.1M | $6.2M | $3.7M | $2.1M | $537.0K | — |
| Stock-based compensation | $18.9M | $18.1M | $16.7M | $11.7M | $5.2M | $354.0K | — |
| Capital expenditure | $4.7M | $4.0M | $19.0M | $12.9M | $9.7M | $3.4M | — |
| Investing cash flow | -$101.8M | -$44.5M | $88.8M | -$219.2M | -$9.7M | -$3.4M | — |
| Financing cash flow | $30.4M | $98.9M | $27.5M | $20.5M | $377.6M | $60.1M | — |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-109360.
Plot the figures US dollars
- Operating cash flow
- Receivables
- Total current assets
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$23.1M | -$59.4M | -$92.5M | -$43.8M | $42.0M | -$22.8M |
| Receivables | — | — | — | — | — | — | — |
| Total current assets | — | $43.6M | $348.7M | $275.9M | $236.2M | $377.4M | $393.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |